Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by ANVISA-Brazil from April 15-April 19, 2024.

Following a successful inspection, the Unit has been issued GMP Certification from ANVISA-Brazil.

The facility is involved in manufacturing various oncology and nononcology APIs. The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.